Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Safety and Benefit of Home-hospitalization Program in the Management of Natalizumab (Tysabri®) Medication in Multiple Sclerosis

NCT04777539 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT04777539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04777539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Safety and Benefit of Home-hospitalization Program in the Management of Natalizumab (Tysabri®) Medication in Multiple Sclerosis
Lead sponsor
Nantes University Hospital
Phase
Observational
Overall status
Completed
Start date
June 14, 2021
Completion date
May 14, 2025
Enrollment
283 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms)